Published: 2010-10-14 17:55:42 CEST
NeuroSearch A/S - Company Announcement
The HART study with Huntexil® shows significant effect on total motor function in patients with Huntington's disease although it did not meet the primary endpoint after 12 weeks of treatment
- The primary endpoint, the modified Motor Score, mMS, measuring voluntary
motor function, showed an improvement of 1.2 points (p= 0.078) 

- The secondary endpoint, the Total Motor Score, TMS, measuring all motor
symptoms of the disease, showed an improvement of 2.8 points (p= 0.039) 

- A statistically significant dose-response relationship was shown for
Huntexil® on both the primary (mMS) and the secondary endpoint (TMS) 

- The results support the good safety and tolerability profile of Huntexil®

- Results are consistent with the results from the MermaiHD study

- NeuroSearch will consult with regulatory authorities to define the best
strategy for obtaining marketing approval for Huntexil® 


Copenhagen, 14 October 2010 - Today, NeuroSearch A/S (NEUR) announced the first
results from the 12-week randomised, double-blinded, placebo-controlled Phase
II HART study with Huntexil® (pridopidine), a novel treatment for Huntington's
disease. 

The HART study was conducted in 28 centres across the United States and Canada
and enrolled a total of 227 patients, who were randomised to treatment with
three different doses of Huntexil® (10 mg, 22.5 mg or 45 mg - all twice daily)
or placebo. 

The primary endpoint of the HART study was the change from baseline at 12-weeks
on the modified Motor Score, mMS, a subscale of the UHDRS (the Unified
Huntington's Disease Rating Scale) Total Motor Score, TMS. For the Huntexil® 45
mg twice daily dose group, the effect versus placebo on the mMS did not reach
significance, but on the secondary endpoint, the TMS, the change from baseline
at week 12 was statistically significant. For both the mMS and the TMS, a
statistically significant improvement in the change from baseline was seen with
increasing dose, thus demonstrating an important dose-response relationship for
Huntexil®. 

Importantly, the effect sizes for both the mMS and the TMS seen in the HART
study are consistent with those seen in the MermaiHD study (see table): 
 
Table: 	Huntexil® (45 mg twice daily) - effect on mMS and TMS (mean change
versus placebo; p-value) 

	The HART study*	The MermaiHD study  at 12 weeks**	The MermaiHD study at 26
weeks*** 
mMS	-1.2 (p= 0.078)	-0.6 (p= 0.2)	-1.0 (p= 0.042)
TMS	-2.8  (p= 0.039)	-2.0 (p= 0.032)	-3.0 (p= 0.004)
* 	ANCOVA (ITT, LOCF) adjustment for baseline score, age, treatment 
** 	MMRM (ITT, OC) adjustment for baseline score, neuroleptics (yes/no),
gender, treatment, week and interaction between treatment and week 
***	ANCOVA (ITT, LOCF) adjustment for baseline score, neuroleptics (yes/no),
gender, treatment 

In the HART study, Huntexil® 45 mg twice daily also showed significant effects
on the patients' balance and gait as well as hand movements. For the TMS motor
domains for eye movements, dystonia and chorea, positive trends were observed.
In general, these results also show consistency with the observations in the
MermaiHD study. 

The endpoints for cognition, affective symptoms and generalised
function/well-being did not show any statistically significant changes. 

In the HART study, Huntexil® was found safe and well tolerated, and the most
frequently reported adverse events across all treatment groups were falls,
headache, diarrhoea and nausea with no apparent pattern related to active
treatment. The adverse event findings were consistent with the observations in
the MermaiHD study. Compliance with study medication was high across the study. 

Treatment was discontinued due to adverse events for 7% of patients, and nine
serious adverse events (recurrent breast cancer, suicidal ideation, depression,
bipolar disorder, adjustment disorder, testicular torsion and three episodes of
convulsions) were reported in six patients. No dose-dependent clinical patterns
related to active treatment were observed. 

Dr. Karl Kieburtz, University of Rochester Medical Center, Rochester, New York,
the US, Primary Investigator on the HART study, commented: 

"I find the results of the HART study encouraging as they provide additional
support for the efficacy of pridopidine (Huntexil®) while helping also to
demonstrate its benign safety profile in patients with Huntington's disease.
Pridopidine is the first drug ever to target both the voluntary and involuntary
motor features of this disease." 

Patrik Dahlen, CEO of NeuroSearch, added:

"We are highly encouraged by the supportive HART study outcome and we look
forward to taking the next steps towards our goal of establishing Huntexil® as
a new and better treatment option for patients with Huntington's disease." 

NeuroSearch is very encouraged by the strong trend in improvement on mMS, as
well as the significant improvement on TMS and other secondary motor endpoints
seen with Huntexil® in the HART study. This, together with the significant
dose-response relationship on both endpoints provide strong support to previous
clinical findings, demonstrating that the drug has beneficial and relevant
effects on core motor functions in patients with Huntington's disease. Further,
the efficacy of Huntexil has been shown to be associated with a good safety
profile. 

In the coming weeks, additional study analyses will be undertaken, including
meta-analyses of data from both the HART and the MermaiHD studies. When the
evaluation of all available clinical data is completed, NeuroSearch plans to
engage in dialogue with regulatory authorities in North America and in Europe
with a view to discussing the best way forward to obtaining marketing approvals
for Huntexil® as a novel treatment for Huntington's disease. 
 
NeuroSearch holds all commercial rights to Huntexil®, and the company is on a
continuous basis evaluating the best commercial options for the drug in North
America, Europe and the rest of the world. 

The HART results do not change the company's financial guidance for 2010 of a
loss before financials and other shares of results of approximately DKK 350
million. 



Patrik Dahlen	Thomas Hofman-Bang
CEO		Chairman of the Board



Contact persons
Patrik Dahlen, CEO, telephone: +45 2629 7296
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4017 5103 


Conference call
NeuroSearch will host a conference call tomorrow, Friday 15 October, 11:30 am
to 12:00 local time (10:30 to 11:00 am UK time/5:30 to 6:00 am EST) to further
present and discuss the HART results. Participating in the call will be CEO
Patrik Dahlen, Dr. Nicholas Waters, CEO of NeuroSearch Sweden AB and Hanne Leth
Hillman, VP and Director of IR & Capital Market Relations. The telephone
conference will be conducted in English and the dial-in numbers are: UK and
International +44 207 509 5139, US +1 718 354 1226 and DK +45 3271 4767. 



About Huntexil® (pridopidine) 
Pridopidine acts as a dopaminergic stabiliser and is the first compound in a
new class of pharmaceutical agents, dopidines to have demonstrated clinical
effect. Dopidines have the unique ability to stabilise the dopaminergic system,
i.e., to either enhance or inhibit dopamine dependent functions in the brain,
depending on the initial level of dopaminergic activity. 

Pridopidine inhibits dopamine activation of the D2 receptor with a preference
towards the high affinity (activated) receptor state and has no detectable
agonist activity on this receptor. In vivo, pridopidine strengthens glutamate
function in the frontal cortex, which may add to the agent's powerful
behavioural effects in states of excessively high dopamine activity or
excessively low glutamate activity, while not affecting behaviour under normal
conditions. Together, these findings suggest that pridopidine stabilises
psychomotor activity in states of hypo- and hyperactivity by means of
functional D2 antagonism and strengthening of cortical glutamate functions. 


About Huntington's disease
Huntington's disease is a highly disabling, fatal and incurable genetic
disorder, which leads to damage of the nerve cells in certain areas of the
brain including the basal ganglia and the cerebral cortex. The disease is
hereditary and every child of someone with Huntington's disease has a 50%
chance of inheriting the disease. 

Patients with Huntington's disease experience a wide variety of symptoms, which
typically can be grouped into three categories: motor dysfunction includes loss
of muscle co-ordination, parkinsonism, chorea, dystonia, and abnormal gait and
posture, which can markedly impair patients' daily functioning. Impaired
executive and cognitive functions lead to loss of organizational and planning
skills, and psychiatric changes, such as depression and anxiety, are typical;
manic and psychotic symptoms can also be present. The onset of symptoms is
typically around 35-45 years of age, after which patients deteriorate gradually
and have a life expectancy of 10-20 years. 
 
Patients with Huntington's disease will eventually require full-time care, and
the therapy area has high unmet medical needs. No cure or effective treatment
is available and only a limited number of novel drugs are in development. The
prevalence of Huntington's disease is about 1: 10 000 in most western
countries, corresponding to an estimated 70 000 affected patients in North
America and Europe combined. In other parts of the world, the prevalence varies
substantially and is generally lower. 


About NeuroSearch 
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system,
and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel drug to treat obesity. 

NeuroSearch is founded on a well-established drug discovery platform in the
field of ion channels and monoamine transporters, ensuring the continuous
production of novel preclinical development candidates. The company has
strategic drug discovery and development alliances with Janssen Pharmaceutica
and Eli Lilly as well as a licence collaboration with Abbott. Further,
NeuroSearch has equity interests in a number of private companies in the Life
Science industry.


fonds.21-10 - hart study results - uk.pdf
facade_04_beskåret.jpg